Kahlenborn, C., Modugno, F., Potter, D. M., & Severs, W. B. (2006). Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clinic Proceedings, 81(10), 1290-1302. https://doi.org/10.4065/81.10.1290
Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clin Proc. 2006;81(10):1290-1302. doi:10.4065/81.10.1290
Kahlenborn, Chris, et al. "Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis." Mayo Clinic Proceedings, vol. 81, no. 10, 2006, pp. 1290-1302.
The Polycarp Research Institute, Enola, PA, USA01mkye871
Penn State Milton S. Hershey Medical Center01h22ap11
Linked to ROR, the Research Organization Registry
RRM Academy Synopsis
Oral contraceptive use is linked to premenopausal breast cancer
Premenopausal women who had used oral contraceptives had higher odds of breast cancer (odds ratio 1.19) in a 2006 meta-analysis of 34 case-control studies. Among women with a birth, the odds were highest after 4 or more years of use before a first full-term pregnancy (odds ratio 1.52).
Key Findings
In premenopausal women or women younger than 50, pill use had a pooled odds ratio of 1.19 (95% CI, 1.09-1.29). Of 37 analyzed study groups, 29 had odds ratios above 1.
In parous women (those with at least one birth), ever use carried an odds ratio of 1.29 (95% CI, 1.20-1.40). In women with no prior births, it was 1.24 (95% CI, 0.92-1.67).
In parous women, use before a first full-term pregnancy (FFTP) carried an odds ratio of 1.44 (95% CI, 1.28-1.62). Use after FFTP carried 1.15 (95% CI, 1.06-1.26).
Parous women who used oral contraceptives 4 or more years before FFTP had the highest odds ratio: 1.52 (95% CI, 1.26-1.82).
In women with no prior births, use for 4 or more years had an odds ratio of 1.29 (95% CI, 0.85-1.96).
Interpretation
The analysis pools case-control studies, a design that compares women who have breast cancer with women who do not and asks about past pill use. The 34 studies yielded 39 study groups, and 37 of them reported whether women had ever used the pill, the groups behind the overall estimate. The authors read the pooled result as an increased risk in women younger than 50, greatest for parous women who used pills before a first full-term pregnancy. They state that they could not control for the hormone doses, which changed over the years.
RRM Context
Restorative reproductive medicine works with the ovulatory cycle and looks for the cause of cycle symptoms. Oral contraceptives are suppressive medications that override the cycle. The pooled studies link them to breast cancer in premenopausal women.
Our editorial summary of this paper, not the article's abstract.
Abstract
Objective
To perform a meta-analysis of case-control studies that addressed whether prior oral contraceptive (OC) use is associated with premenopausal breast cancer.
Methods
We searched the MEDLINE and PubMed databases and bibliography reviews to identify case-control studies of OCs and premenopausal breast cancer published in or after 1980. Search terms used included breast neoplasms, oral contraceptives, contraceptive agents, and case-control studies. Studies reported in all languages were included. Thirty-four studies were identified that met inclusion criteria. Two reviewers extracted data from original research articles or additional data provided by study authors. We used the DerSimonian-Laird method to compute pooled odds ratios (ORs) and confidence intervals (CIs) and the Mantel-Haenszel test to assess association between OC use and cancer.
Results
Use of OCs was associated with an increased risk of premenopausal breast cancer in general (OR, 1.19; 95% CI, 1.09-1.29) and across various patterns of OC use. Among studies that provided data on nulliparous and parous women separately, OC use was associated with breast cancer risk in both parous (OR, 1.29; 95% CI, 1.20-1.40) and nulliparous (OR, 1.24; 95% CI, 0.92-1.67) women. Longer duration of use did not substantially alter risk in nulliparous women (OR, 1.29; 95% CI, 0.85-1.96). Among parous women, the association was stronger when OCs were used before first full-term pregnancy (FFTP) (OR, 1.44; 95% CI, 1.28-1.62) than after FFTP (OR, 1.15; 95% CI, 1.06-1.26). The association between OC use and breast cancer risk was greatest for parous women who used OCs 4 or more years before FFTP (OR, 1.52; 95% CI, 1.26-1.82).
Conclusion
Use of OCs is associated with an increased risk of premenopausal breast cancer, especially with use before FFTP in parous women.